By buying Canadian biotech Encycle Therapeutics Inc., Denmark-based Zealand Pharma AS has acquired its first external asset and with it a novel treatment for gastrointestinal disease plus an extensive screening library which could provide additional targets for the Danish group’s research.
The acquisition, announced on 22 October, is centered around Encycle’s preclinical product ET3764, an orally delivered peptide targeting the alpha-4-beta-7...








